TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Dr. Lal Path Labs Ltd.
LALPATHLAB

Dr. Lal Path Labs Ltd. Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 72/100 · Good See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹1,952.3

Change

-9.0 (-0.46%)

Open

₹1,980.0

Prev. Close

₹1,961.3

Day High

₹1,986.8

Day Low

₹1,902.7

Volume Analysis

Traded

452,137

Delivered

151,424

Delivery %

33.49%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (22.3%)
  • •Strong operating margin (29.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (1)

  • •Strong 3-year EPS growth (28.1%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹2,075.94 ₹2,031.37 ₹1,991.84 ₹1,947.27 ₹1,907.74 ₹1,863.17 ₹1,823.64
Fibonacci ₹2,031.37 ₹1,999.24 ₹1,979.4 ₹1,947.27 ₹1,915.14 ₹1,895.3 ₹1,863.17
Camarilla ₹1,975.43 ₹1,967.72 ₹1,960.01 ₹1,947.27 ₹1,944.59 ₹1,936.88 ₹1,929.17

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+29.31%

1 Week

+1.66%

1 Month

+1.1%

3 Months

+18.59%

6 Months

+47.5%

1 Year

-38.89%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹318.89

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

20.78%

Net margin 18.89% × asset turnover 0.88x × equity multiplier 1.25x

Company Overview

Sector

Healthcare

Market Cap

₹32,299 Cr

P/E (TTM)

57.4

ROE

22.3%

Book Value

₹150.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.

TopFund Analysis

Dr. Lal Path Labs Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 72/100. The strongest factor is Financial Strength (100/100), while Valuation (3/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (22.3%); strong operating margin (29.0%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

72/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

67

Valuation

3

Cash Flow

99

Corporate Governance

61

Momentum

85

Institutional Ownership

60

Business Quality

96

Risk & Volatility

60

Liquidity

63

From Screener.in

  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 36.4%
  • −Stock is trading at 12.9 times its book value
  • −The company has delivered a poor sales growth of 11.8% over past five years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Sep 04 Sep
Announcement under Regulation 30 (LODR)-Updates on Acquisition 27 Aug

Dr. Lal Ventures completed 30% stake subscription in Neuome Technologies on August 27, 2026; Neuome became associate.

Incorporation Of A Step-Down Subsidiary Company 19 Aug

Dr Lal PathLabs incorporated Dr Lal PathLabs Indomed LLC in Tashkent, Uzbekistan; 70% stake subscribed.

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 6 Aug 06 Aug
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 30 Jul 30 Jul

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 541 601 539 545 602 660 597 603 670 731 660 703 798
Expenses + 395 424 398 401 432 458 443 434 478 506 480 516 550
Operating Profit 146 178 141 145 170 202 154 169 192 224 179 187 248
OPM % 27.0% 30.0% 26.0% 27.0% 28.0% 31.0% 26.0% 28.0% 29.0% 31.0% 27.0% 27.0% 31.0%
Other Income + 14 18 18 18 21 22 25 26 28 25 -6 24 32
Interest 8 8 7 7 6 6 5 5 5 5 7 6 6
Depreciation 35 36 36 37 35 35 36 36 35 40 42 45 44
Profit before tax 118 152 116 120 150 183 138 153 181 204 124 160 229
Tax % 29.0% 27.0% 29.0% 28.0% 28.0% 29.0% 29.0% -1.0% 26.0% 25.0% 26.0% 17.0% 25.0%
Net Profit + 84 111 82 86 108 131 98 156 134 152 91 132 170
EPS in Rs 5 7 5 5 6 8 6 9 8 9 5 8 10
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 660 791 912 1,057 1,203 1,330 1,581 2,087 2,017 2,227 2,461 2,763 2,891
Expenses + 504 582 675 793 910 987 1,145 1,526 1,527 1,617 1,764 1,979 2,053
Operating Profit 156 210 238 264 294 344 436 561 490 609 698 783 838
OPM % 24.0% 26.0% 26.0% 25.0% 24.0% 26.0% 28.0% 27.0% 24.0% 27.0% 28.0% 28.0% 29.0%
Other Income + 12 20 27 31 46 55 51 52 42 69 91 70 75
Interest 0 0 1 1 1 15 16 30 38 29 22 23 24
Depreciation 28 28 28 33 38 73 77 108 150 144 142 162 172
Profit before tax 140 201 237 261 301 310 394 475 344 505 625 669 717
Tax % 31.0% 34.0% 34.0% 34.0% 33.0% 27.0% 25.0% 26.0% 30.0% 28.0% 21.0% 24.0% —
Net Profit + 96 133 156 172 200 228 296 350 241 362 492 510 546
EPS in Rs 9 8 9 10 12 14 17 21 14 21 29 30 32
Dividend Payout % 9.0% 15.0% 16.0% 22.0% 25.0% 44.0% 57.0% 29.0% 42.0% 0.0% 41.0% 68.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 260 425 512 705 862 949 1,162 1,418 1,583 1,766 2,089 2,341
Borrowings + 27 0 0 0 0 0 150 533 420 247 157 199
Other Liabilities + 134 118 95 128 145 341 265 309 297 357 383 433
Total Liabilities 475 625 690 916 1,091 1,374 1,661 2,343 2,383 2,454 2,713 3,140
Fixed Assets + 150 166 152 208 209 413 447 1,369 1,305 1,228 1,168 1,256
CWIP 1 4 18 10 3 11 10 15 5 6 3 7
Investments 38 64 106 145 185 164 59 65 150 114 327 423
Other Assets + 286 391 414 554 694 786 1,144 893 923 1,107 1,215 1,454
Total Assets 475 625 690 916 1,091 1,374 1,661 2,343 2,383 2,454 2,713 3,140
Equity Capital 55 83 83 83 83 83 83 83 83 83 84 168

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 122 159 171 197 219 284 398 447 456 535 569 636
Cash from Investing Activity + -113 -163 -137 -172 -100 -26 -212 -449 -287 -24 -303 -422
Cash from Financing Activity + -1 0 -32 13 -55 -190 -139 136 -283 -414 -334 -264
Net Cash Flow 8 -5 2 37 64 67 48 134 -114 97 -68 -50
CFO/OP 112 108 102 110 110 110 115 103 115 110 105 104
Free Cash Flow 87 115 120 125 177 205 339 -28 412 479 516 463

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 54.61% → 53.19%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Others 0.41% 0.37% 0.32% 0.3% 0.33% 0.28% 0.27% 0.39% 0.37% 0.35% 0.34% 0.38%
Public 11.48% 10.12% 9.24% 6.95% 6.02% 5.82% 5.84% 6.22% 6.07% 6.94% 7.88% 7.48%
Promoters 54.61% 54.6% 54.6% 54.6% 53.92% 53.91% 53.91% 53.79% 53.21% 53.21% 53.21% 53.19%
Government 0.29% 0.29% 0.29% 0.29% 0.29% 0.29% 0.29% 0.29% 0.27% 0.01% 0.01% 0.01%
FII 24.35% 25.36% 26.15% 25.43% 26.82% 26.82% 23.9% 21.69% 21.86% 20.29% 17.18% 17.35%
DII 8.85% 9.27% 9.4% 12.42% 12.6% 12.88% 15.79% 17.62% 18.22% 19.2% 21.37% 21.59%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Dr. Lal Path Labs Ltd. (this stock) 32,299 57.4 12.83 22.3%
Krishna Inst Of Med Sci L 32,765 157.0 13.88 11.3%
Sai Life Sciences Limited 33,821 92.0 13.61 15.4%
Neuland Lab Ltd. 28,085 56.4 14.98 21.2%
Piramal Pharma Limited 28,000 — 3.42 -3.83%
Wockhardt Limited 36,814 92.3 7.45 6.11%
Rubicon Research Limited 27,748 96.3 21.46 27.0%

Which Mutual Funds Hold Dr. Lal Path Labs Ltd.?

Frequently Asked Questions about Dr. Lal Path Labs Ltd.

Community Sentiment

What are other investors saying about Dr. Lal Path Labs Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.